Human Monoclonal Antibody (Mab) Development for Walter Reed Army Institute of Research... Tender

Procurement Summary

Country : USA

Summary : Human Monoclonal Antibody (Mab) Development for Walter Reed Army Institute of Research (Wrair), Armed Forces Research Institute of Medical Sciences (Wrair-Afrims)

Deadline : 30 Apr 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 100031583

Document Ref. No. : HT942524Q0057

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Purchaser : DEPT OF DEFENSE
Contracting Office Address : FORT DETRICK, MD 21702
Primary Point of Contact : Flodean Billings
flodean.p.billings.civ@health.mil
Phone Number 3016192648

Secondary Point of Contact : Jennifer Hayden
jennifer.e.hayden.civ@health.mil
USA
Email :flodean.p.billings.civ@health.mil

Tender Details

Description

The U.S. Army Medical Research Acquisition Activity (USAMRAA) in support of the Walter Reed Army Institute of Research (WRAIR) Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS) intends to negotiate solely (as prescribed in FAR 13.106(b)(1)(i)) with Genovac Antibody Discovery, LLC located at 1810 NDSU Research Circle N, Suite B, Fargo, ND 58102 to perform feasibility studies for the development and production of a panel of fully human mAbs for AFRIMS-supplied target antigens or using AFRIMS-supplied cultured B cells for use in developing immunotherapeutic against bacterial pathogens associated with wound infection and sepsis. This shall include immunization in transgenic animal model expressing fully human Immunoglobulin G (IgG) antibodies, high-throughput single-cell screening for antigen-specific Antibody-Secreting Cells (ASCs) and cloning and expression of recombinant mAbs for two (2) years.

The North American Industry Classification System (NAICS) for this requirement is 541714 and the size standard is 1, 000.

This announcement constitutes the only notice by the government; a written solicitation will not be issued. All sources that believe they are eligible to provide these items must respond in writing. Responses must be supported with clear and convincing evidence to clearly articulate the ability to provide the items outlined above. A request for documentation will not be considered an affirmative response. This Special Notice of Intent is not a request for competitive quotes. Information received will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. If no written responses are received by the date listed below, the purchase will be awarded without further remark. All questions and responses concerning this notice shall be emailed to Ms. Flodean Billings at flodean.p.billings.civ@health.mil.

Interested concerns must identify their capabi...
Active Contract Opportunity Notice ID HT942524Q0057 Related Notice PANMRA24P0000002219 Department/Ind. Agency DEPT OF DEFENSE Sub-tier DEFENSE HEALTH AGENCY (DHA) Office ARMY MED RES ACQ ACTIVITY
General Information
Contract Opportunity Type: Special Notice (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Apr 15, 2024 08:44 am EDT
Original Response Date: Apr 30, 2024 10:00 am EDT
Inactive Policy: 15 days after response date
Original Inactive Date: May 15, 2024
Initiative: None

Classification
Original Set Aside:
Product Service Code: AN11 - Health R&D Services; Health care services; Basic Research
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance: Silver Spring, MD 20901 USA

Documents

 Tender Notice